Drug Search Results
More Filters [+]

BMS-986148

Alternative Names: bms-986148, bms986148, bms 986148
Latest Update: 2021-11-16
Latest Update Note: Clinical Trial Update

Product Description

an Anti-mesothelin Antibody-drug Conjugate for Patients with Advanced Solid Tumors (Sourced from: https://pubmed.ncbi.nlm.nih.gov/34615718/)

Mechanisms of Action: Mesothelin Inhibitor

Novel Mechanism: Yes

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BMS-986148

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Non-Small-Cell Lung Cancer|Pancreatic Cancer|Mesothelioma|Ovarian Cancer|Small Cell Lung Cancer|Gastrointestinal Cancer|Oncology Solid Tumor Unspecified

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2014-002485-70

P2

Completed

Oncology Solid Tumor Unspecified

2020-05-07

CA008-002

P2

Terminated

Gastrointestinal Cancer|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Mesothelioma|Small Cell Lung Cancer|Ovarian Cancer

2019-02-25

JapicCTI-163412

P1

Terminated

Oncology Solid Tumor Unspecified

2017-11-01

CA008-008

P1

Completed

Oncology Solid Tumor Unspecified

2017-09-06

41%

Recent News Events

Date

Type

Title